Biocon’s biosimilar for treating Covid-19: Patients responded positively, says Kiran Mazumdar-Shaw

The Drug Controller General of India (DGCI) has permitted the Bengaluru-headquartered drug maker to market Itolizumab (ALZUMab) injection 25 mg/5 mL solution for emergency use in India for treating cytokine release syndrome (CRS) in moderate to severe ARDS (acute respiratory distress syndrome) Covid patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3iUCD8U
via IFTTT